|
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation |
Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technology Assessment 2011; 15(10): 1-329 Authors' objectives To determine the clinical effectiveness, safety and cost-effectiveness of etanercept, infliximab and adalimumab for the treatment of active and progressive PsA in patients who have an inadequate response to standard treatment (including DMARD therapy).
Authors' conclusions Review found that etanercept, infliximab and adalimumab are efficacious in the treatment of psoriatic arthritis compared with placebo, with beneficial effects on joint symptoms, functional status and skin. Length of follow-up in trials was limited but the evidence to support the use of these biologic agents is convincing, given the size of treatment effect and quality of the data. INAHTA brief and checklist Indexing Status Subject indexing assigned by CRD MeSH Anti-Inflammatory Agents; Antibodies, Monoclonal; Arthritis, Psoriatics; Tumor Necrosis Factor-alpha Language Published English Country of organisation England Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32010000260 Date abstract record published 14/04/2010 |
|
|
|